

Early information

6th & 7th

April

2017

1st edition

Munich
Germany



Stroke Prevention and Management Guidelines **Forum**

Better understand the stroke
guidelines development process
and its implications

Why a Guidelines Forum[®] on Stroke Prevention and Management

The objective is to better understand the existing stroke guidelines development process and its implications in clinical practice. It is not to develop new guidelines, but to gather a multidisciplinary panel of leading international experts to discuss the latest evidence, ongoing research and controversial issues that have implications for the development of clinical practice guidelines.

The burden of stroke is of major importance for global public health. In 2013, according to the Global Burden of Disease study, there were 10.3 million new strokes (including 67% of ischaemic strokes (IS), 6.5 million deaths from stroke (51% from IS), 113 million DALYs due to stroke (58% due to IS) and almost 25.7 million stroke survivors (71% with IS). In the United States, stroke accounted for approximately 1 of every 20 deaths; on average, every 4 minutes, someone died of a stroke. Globally, the proportional contribution of stroke-related DALYs and deaths due to stroke compared to all diseases increased from 1990 to 2013.

Clinical practice guidelines and associated implementation strategies are essential to promote optimal, evidence-based practices in stroke prevention and management.

Clinical practice Guidelines

Current European and North American guidelines cover the following areas:

- acute stroke management
- primary stroke prevention
- stroke prevention in women
- secondary stroke prevention
- stroke prevention in patients with non-valvular atrial fibrillation

While current practice guidelines are generally in agreement, specific recommendations may differ, reflecting diverging interpretations of the available evidence or the lack of sufficient data to make evidence-based recommendations. In addition, a number of questions arise as a result of a rapidly changing clinical landscape.

About TMA

The Translational Medicine Academy (TMA) is an international academic Foundation with focused activities in Mission Critical Areas of high public health importance having significant professional and patient therapeutic and educational gaps.

Format

A series of short presentations and discussions with a focus on practical examples, case studies and interactivity between Faculty members.

Who should attend?

Attendees include industry representatives with interest in clinical trials, product development, market access, guidelines development and implementation, patients' advocacy specialists, clinical research organizations and payers.

An opportunity to meet a panel of international experts in stroke management and prevention

GUIDELINES FORUM® CO-CHAIRS



Prof. Hans-Christoph Diener

MD, PhD, FAHA, FAAN
Senior Professor for
Clinical Neurosciences -
Department of Neurology
University
Duisburg-Essen, Germany


Hans-Christoph Diener is Senior Professor for Clinical Neurosciences Department of Neurology at the University Duisburg-Essen. He was President of the German Neurological Society (2003-2004), the European Headache Federation (2006-2008) and the International Headache Society (2009-2011). Dr. Diener's special research interests focus on stroke, headache and cerebellar physiology. He has set up the first acute stroke unit in Germany in 1995. He was and is the principal investigator of major trials in the acute therapy and prevention of stroke

and participated in the recent trials on NOACs in stroke prevention in atrial fibrillation. Prof. Diener has authored or co-authored 847 articles in peer reviewed journals and served as the editor or author of 77 books. He serves on the editorial boards of several high impact factor journals.

Dr. Connolly holds a Masters degree from Fordham University, New York, and an MD from McGill University in Montreal. He received his specialist training in cardiology at the University of Toronto and at Stanford University. Dr. Connolly became a faculty member at McMaster University in 1983 and was awarded a full professorship in 1994. He has published more than 270 scientific articles in the field and is currently a member of the editorial boards for a number of prominent Cardiology journals.

Prof. Stuart J. Connolly

MD, FRCP(C)
Professor of Medicine at
McMaster University and a Cardiac
Electrophysiologist at Hamilton
Health Sciences
Canada



Why attend a Guidelines Forum®?

- The development and successful implementation of guidelines requires both communication and transparency between all stakeholders. The Guidelines Forum is a closed workshop during which meaningful discussions occur between academic faculty members covering relevant topics for industry attendees.
 - A better understanding of the processes involved in guidelines development and implementation will help attendees that develop drugs, biomarkers and devices, to adapt and improve their research and development programs for the future.
 - Case based discussions: the success and failure stories that inevitably accompany the release of new guidelines may be a source of inspiration for further research and development.
 - Guidelines really shape clinical practice if doctors and their patients adopt them. Therefore, implementation is essential. This could also translate into earlier and more efficient development of diagnostic and therapeutic tools for patients.
- At the end of the meeting, all participants will have a better understanding of the unmet needs and knowledge gaps that need to be addressed by future research and development efforts, and of the most appropriate ways of progressing to conciliate and take advantage of clinical, societal, evidence-based medicine and regulatory requirements.

Preliminary Agenda

- Guidelines development process
- Guidelines and awareness campaigns
- Stroke management recommendations
- Stroke prevention recommendations
- Specific patient populations
- Guidelines implementation
- Case-based discussions and scenarios
- Health economic perspectives
- Latest clinical developments

Faculty

It will include a Faculty of 15 experts, either international guideline writers, reviewers and independent experts, as well as regulatory representatives from Europe, North America and Asia.

Presentations are not handed out and there will be no published proceedings.

SOME OF THE CONFIRMED EXPERTS:

- Pierre Amarenco, Paris, France
- Mayank Goyal, Calgary, Canada
- Paulus Kirchhof, Birmingham, UK
- Thorsten Lewalter, Munich, Germany
- George Ntaios, Larissa, Greece
- Tatjana S. Potpara, Belgrade, Serbia
- Horst Sievert, Frankfurt, Germany
- Thorsten Steiner, Heidelberg, Germany
- Götz Thomalla, Hamburg, Germany
- Freek Verheugt, Amsterdam, The Netherlands

Conditions of sales

Cancellation Fees will apply as of receipt of the confirmation for sponsorships and registrations as follows:

- 10% from 26 August 2016 to 31 October 2016
- 50% from 01 November 2016 to 31 January 2017
- 100% from 01 February 2017

Contact us

TMA Foundation

Grant Opportunities (including CME, Advisory Boards & Customized Grants)

William Melhuish / Yann Colardelle

Tel.: + 33 (0) 6 16 54 81 57

E-mail: william@mededgs.com and
yanncol@tmacademy.org

Registration : www.tmacademy.org

